全文获取类型
收费全文 | 857篇 |
免费 | 65篇 |
国内免费 | 28篇 |
专业分类
儿科学 | 61篇 |
妇产科学 | 12篇 |
基础医学 | 78篇 |
口腔科学 | 48篇 |
临床医学 | 113篇 |
内科学 | 165篇 |
皮肤病学 | 13篇 |
神经病学 | 16篇 |
特种医学 | 253篇 |
外科学 | 54篇 |
综合类 | 18篇 |
预防医学 | 31篇 |
眼科学 | 6篇 |
药学 | 46篇 |
肿瘤学 | 36篇 |
出版年
2021年 | 5篇 |
2020年 | 1篇 |
2019年 | 6篇 |
2018年 | 16篇 |
2017年 | 7篇 |
2016年 | 7篇 |
2015年 | 13篇 |
2014年 | 17篇 |
2013年 | 9篇 |
2012年 | 5篇 |
2011年 | 12篇 |
2010年 | 32篇 |
2009年 | 21篇 |
2008年 | 9篇 |
2007年 | 27篇 |
2006年 | 21篇 |
2005年 | 15篇 |
2004年 | 10篇 |
2003年 | 18篇 |
2002年 | 12篇 |
2001年 | 13篇 |
2000年 | 10篇 |
1999年 | 14篇 |
1998年 | 60篇 |
1997年 | 71篇 |
1996年 | 78篇 |
1995年 | 47篇 |
1994年 | 38篇 |
1993年 | 43篇 |
1992年 | 17篇 |
1991年 | 12篇 |
1990年 | 19篇 |
1989年 | 40篇 |
1988年 | 40篇 |
1987年 | 31篇 |
1986年 | 30篇 |
1985年 | 31篇 |
1984年 | 8篇 |
1983年 | 10篇 |
1982年 | 12篇 |
1981年 | 10篇 |
1980年 | 12篇 |
1979年 | 3篇 |
1978年 | 4篇 |
1977年 | 13篇 |
1976年 | 10篇 |
1975年 | 6篇 |
1969年 | 1篇 |
1966年 | 1篇 |
1950年 | 1篇 |
排序方式: 共有950条查询结果,搜索用时 15 毫秒
941.
Watson MS; Carroll AJ; Shuster JJ; Steuber CP; Borowitz MJ; Behm FG; Pullen DJ; Land VJ 《Blood》1993,82(10):3098-3102
Of 1,036 children with newly diagnosed non-T, non-B acute lymphoblastic leukemia (ALL) and a demonstrated cytogenetic abnormality treated on the frontline Pediatric Oncology Group (POG) therapeutic trial 8602, there were 33 patients with trisomy 21 as the sole abnormality. Of these 33, 14 had Down syndrome (DS). Although the non-DS (NDS) trisomy 21 cases tended to be older than the DS cases, there were no other significant differences in clinicobiologic features nor in treatment outcomes between the DS and NDS groups, nor between the entire trisomy 21 group and the other chromosome abnormality group. Among NDS patients with +21 and one additional abnormality, +X, +16, -20, and structural abnormalities involving 6q or 12p were common findings. Kaplan-Meier event-free survival (EFS) curves showed a 4-year EFS of 80% (SE, 12%) in NDS trisomy 21 cases, 71% (SE, 22%) in DS cases with trisomy 21 as the sole abnormality, and 69% (SE, 2%) in cases with other chromosome abnormalities. Trisomy 21 as a sole acquired abnormality in NDS patients suggests a good prognosis. 相似文献
942.
R Veeratterapillay MBK Shaw R Williams P Haslam A Lall M De la Hunt ST Hasan DJ Thomas 《Annals of the Royal College of Surgeons of England》2012,94(8):588-592
INTRODUCTION
Paediatric percutaneous nephrolithotomy (PCNL) has revolutionised the treatment of paediatric nephrolithiasis. Paediatric PCNL has been performed using both adult and paediatric instruments. Stone clearance rates and complications vary according to the technique used and surgeon experience. We present our experience with PCNL using adult instruments and a 28Fr access tract for large renal calculi in children under 18 years.METHODS
All patients undergoing PCNL at our institution between 2000 and 2009 were reviewed. Demographics, surgical details and post-operative follow-up information were obtained to identify stone clearance rates and complications.RESULTS
PCNL was performed in 32 renal units in 31 patients (mean age: 10.8 years). The mean stone diameter was 19mm (range: 5–40mm). Twenty-six cases required single puncture and six required multiple tracts. Overall, 11 staghorn stones, 10 multiple calyceal stones and 11 single stones were treated. Twenty-seven patients (84%) were completely stone free following initial PCNL. Two cases had extracorporeal shock wave lithotripsy for residual fragments, giving an overall stone free rate of 91% following treatment. There was no significant bleeding or sepsis encountered either during the operation or in the post-operative setting. No patient required or received a blood transfusion.CONCLUSIONS
Paediatric PCNL can be performed safely with minimal morbidity using adult instruments for large stone burden, enabling rapid and complete stone clearance. 相似文献943.
O'DONOGHUE DJ; LAWLER W; HUNT LP; ACHESON EJ; MALLICK NP 《QJM : monthly journal of the Association of Physicians》1991,79(1):333-350
Fifty-four adults with primary mesangial proliferative glomerulonephritisand IgM deposition were observed for a minimum of three yearsor until end-stage renal failure. The actuarial renal survivalwas 80 per cent at 5 years and 64 per cent at 10 years; multivariateanalysis identified microscopic haematuria, extent of mesangialproliferation and global glomerular sclerosis as independentprognostic indicators. 相似文献
944.
目的:观察芪丹颗粒对博莱霉素致肺纤维化鼠的Ⅰ型前胶原和Ⅲ型前胶原mRNA表达的影响,探讨其作用机制。方法:实验于2004-10/2006-10在山东省医学科学院基础所病理实验室完成。实验材料:清洁级雄性SD大鼠160只,体质量180~210g。氢化可的松琥珀酸钠50mg/支;芪丹(颗粒剂)是由黄芪、丹参、川芎等中草药加工提纯后的粗提取物制成的颗粒剂,10g/包(1g干粉相当于原生药8g)。实验分组:160只SD大鼠按随机区组设计分为正常组20只、模型组40只、芪丹颗粒剂50只、氢化可的松50只。实验干预:正常组20只气管内灌注和灌胃均用生理盐水。其余大鼠经气管内一次性灌注博莱霉素A5按0.25mL左右(5mg/kg体质量)诱导大鼠肺间质纤维化。随机取40只为模型组。取芪丹颗粒剂组和氢化可地松组大鼠各30只,分别从造模后第2天灌注芪丹颗粒剂(3125mg/kg)和腹腔注射氢化可的松(25mg/kg),药物干预后第7,14,28天麻醉下处死动物。两组各余20只分别从造模14d后灌注芪丹颗粒剂和腹腔注射氢化可的松(用量同前),于第28、42天分别处死动物。实验评估:用苏木精-伊红评价肺组织病理学变化和原位杂交方法检测各组大鼠肺Ⅰ型和Ⅲ型前胶原mRNA表达。结果:160只大鼠全部进入结果分析。①大鼠肺脏大体标本观察:对照组肺组织各观察时间点无明显改变,模型组肺组织表面凸凹不平,部分肺叶体积缩小,表面见灰白色结节。氢化可的松组与模型组相似。芪丹颗粒剂组见部分肺叶表面不光滑及大小不等结节。②肺组织病理学观察:模型组7d肺泡腔内大量巨噬细胞淋巴细胞中性粒细胞浸润,肺间质成纤维细胞增殖,28d肺泡结构破坏肺泡内见大量胶原纤维和成纤维细胞。芪丹颗粒剂组肺泡炎及肺纤维化程度均明显轻于模型组和氢化可的松组(P<0.05)。③肺间质纤维化形成中Ⅰ型、Ⅲ型前胶原mRNA表达:原位杂交显示两种前胶原mRNA表达呈动态变化,早期肺泡炎以Ⅲ型前胶原mRNA大量增生为主,晚期纤维化期以Ⅰ型前胶原mRNA增生为主。芪丹颗粒剂组Ⅲ型前胶原mRNA的表达在第14天处于最高,至28d仍维持较高的水平,芪丹颗粒剂组Ⅲ型前胶原mRNA的表达高于模型组和氢化可的松组(P<0.05)。28d,Ⅰ型前胶原mRNA的表达在第二天给药芪丹颗粒剂组和氢化可地松组及第14天给药芪丹颗粒剂组和氢化可的松组组间差异均有显著性(P<0.05)。结论:大鼠肺纤维化的早期以Ⅲ型前胶原mRNA的表达为主,晚期纤维化期以Ⅰ型前胶原mRNA的大量表达为主。芪丹颗粒可减轻博莱霉素诱导的大鼠肺泡炎及肺纤维化的程度,其机制可能通过影响了Ⅰ型和Ⅲ型前胶原mRNA的代谢和表达,从而减慢肺间质纤维化的进程。芪丹颗粒对肺间质纤维化有治疗作用,且优于氢化可的松。 相似文献
945.
目的:肾移植术后半年内发生的并发症主要为感染,尤以肺部感染为重。静脉注射大剂量免疫球蛋白预防肾移植术后早期肺部感染的效果值得临床应用中予以总结提高。方法:①实验对象及分组:选择2002-01/2006-12于海南省人民医院肾内科就诊的肾移植术后半年内患者40例,对实验及治疗方案均知情同意,且得到医院伦理道德委员会批准。按随机数字表法分为2组,免疫球蛋白组、对照组各20例。②实验分组:免疫球蛋白组在应用免疫抑制剂基础上用0.4g/(kg·d)免疫球蛋白治疗;对照组应用免疫抑制剂。③实验评估:观察两组患者普通肺炎、重症肺炎发生率及血清IgG和T淋巴细胞亚群水平变化。结果:40例患者全部进入结果分析。①免疫球蛋白组患者的普通肺炎感染率及重症肺炎感染率均低于对照组(P<0.01)。②免疫球蛋白组患者血IgG、T淋巴细胞亚群CD3 ,CD4 ,CD8 水平均高于对照组(P<0.05),用免疫球蛋白治疗未见副作用。结论:随机对照结果显示,肾移植术后早期应用大剂量免疫球蛋白能明显减少肺部感染发生,减少并发症,提高肾移植患者生存率。 相似文献
946.
Weeks RA; Turjanski N; Brooks DJ 《QJM : monthly journal of the Association of Physicians》1996,89(6):401-408
We discuss the clinical characteristics of tics and Tourette's syndrome
(TS) and also possible treatment options. Based upon an overview of
published pathophysiological and PET data, and the results of a recent PET
study of changes in opioid receptor binding in TS, we hypothesize that the
disease arises due to dysfunction within the cingulate and orbitofrontal
cortex. The beneficial effects of dopamine receptor antagonists and
dopamine-depleting agents in TS are suggested to be mediated via basal
ganglia-thalamo-frontal circuits, while opioid agents may act directly on
the cingulate.
相似文献
947.
948.
Two-generation reproduction and cross-foster studies of perfluorooctanesulfonate (PFOS) in rats 总被引:22,自引:0,他引:22
Perfluorooctanesulfonate (PFOS) is a persistent acid found widely distributed in wildlife and humans. To understand the potential reproductive and developmental effects of PFOS, a two-generation reproduction study was conducted in rats. Male and female rats were dosed via oral gavage at dose levels of 0, 0.1, 0.4, 1.6, and 3.2 mg/(kg day) for 6 weeks prior to mating, during mating, and, for females, through gestation and lactation, across two generations. Due to substantial F1 neonatal toxicity observed in the 1.6 and 3.2 mg/(kg day) groups, continuation into the second generation was limited to F1 pups from the 0, 0.1, and 0.4 mg/(kg day) groups. No adverse effects were observed in F0 females or their fetuses upon caesarean sectioning at gestation day 10. Statistically significant reductions in body-weight gain and feed consumption were observed in F0 generation males and females at dose levels of 0.4 mg/(kg day) and higher, but not in F1 adults. PFOS did not affect reproductive performance (mating, estrous cycling, and fertility); however, reproductive outcome, as demonstrated by decreased length of gestation, number of implantation sites, and increased numbers of dams with stillborn pups or with all pups dying on lactation days 1-4, was affected at 3.2 mg/(kg day) in F0 dams. These effects were not observed in F1 dams at the highest dose tested, 0.4 mg/(kg day). Neonatal toxicity in F1 pups, as demonstrated by reduced survival and body-weight gain through the end of lactation, occurred at a maternal dose of 1.6 mg/(kg day) and higher while not at dose levels of 0.1 or 0.4 mg/(kg day) or in F2 pups at the 0.1 or 0.4 mg/(kg day) dose levels tested. In addition to these adverse effects, slight yet statistically significant developmental delays occurred at 0.4 (eye opening) and 1.6 mg/(kg day) (eye opening, air righting, surface righting, and pinna unfolding) in F1 pups. Based on these data, the NOAELs were as follows: reproductive function: F0> or =3.2 and F1> or =0.4 mg/(kg day); reproductive outcome: F0=1.6 and F1> or =0.4 mg/(kg day); overall parental effects: F0=0.1 and F1> or =0.4 mg/(kg day); offspring effects: F0=0.4 and F1> or =0.4 mg/(kg day). To distinguish between maternal and pup influences contributing to the perinatal mortality observed in the two-generation study, a follow-up cross-foster study was performed. Results of this study indicated that in utero exposure to PFOS causally contributed to post-natal pup mortality, and that pre-natal and post-natal exposure to PFOS was additive with respect to the toxic effects observed in pups. 相似文献
949.
950.